



Advances Research in Traumatic Encephalopathy

Guest Editor:

Dr. Brandon Lucke-Wold

Department of Neurosurgery,
School of Medicine, West Virginia
University, Morgantown, WV
26506, USA

Deadline for manuscript
submissions:

closed (31 May 2022)

Message from the Guest Editor

The focus of this edition is on the advancements in understanding the pathology of traumatic encephalopathy and how these advances can be used to improve treatment. We are seeking articles related to fundamental “bench” research in addition to pharmaceutical advancement. In particular, we wish to focus on the pathological mechanisms of and treatment strategies for traumatic encephalopathy. Along these lines, we are also interested in articles discussing novel aspects of the pathophysiology related to the disease and how these molecular pathways may be targeted. Interdisciplinary team approaches attacking the problem from multiple different angles will be of interest to our readership. We are hoping to serve as a catalyst for sparking further discovery.

Dr. Brandon Lucke-Wold

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)